Literature DB >> 11765112

Drug product selection: legal issues.

T P Christensen1, D M Kirking, F J Ascione, L S Welage, C A Gaither.   

Abstract

OBJECTIVE: To review the potential legal liability of the pharmacist in the drug product selection process. DATA SOURCES: Published articles identified through MEDLINE, published law reviews identified through InfoTrac, and appellate court decisions. Search terms used included pharmacist liability, drug product selection, and generic substitution. Additional articles, books, and appellate court decisions were identified from the bibliographies of retrieved articles and citations in appellate court decisions. DATA SYNTHESIS: Pharmacists engaging in drug product selection are civilly liable under three legal theories: negligence, express or implied warranties, and strict product liability. Potential criminal liability includes prosecution for insurance fraud, deceptive business practices, and violation of state drug product selection laws and regulation.
CONCLUSION: Pharmacists increase their liability when engaging in drug product selection, but the increase is small. Still, the law continues to evolve as pharmacists seek expanded roles and responsibilities. When courts give closer examination to pharmacists' expanded role, it is likely that pharmacists' liability will increase.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11765112     DOI: 10.1016/s1086-5802(16)31328-6

Source DB:  PubMed          Journal:  J Am Pharm Assoc (Wash)        ISSN: 1086-5802


  3 in total

1.  Predictors of statin compliance after switching from branded to generic agents among managed-care beneficiaries.

Authors:  Robert J Romanelli; Jodi B Segal
Journal:  J Gen Intern Med       Date:  2014-06-24       Impact factor: 5.128

2.  Understanding patients' perspective in the use of generic antiepileptic drugs: compelling lessons for physicians to improve physician/patient communication.

Authors:  Kore Liow
Journal:  BMC Neurol       Date:  2009-03-17       Impact factor: 2.474

3.  Considerations for the US health-system pharmacist in a world of biosimilars.

Authors:  Andrea Zlatkus; Todd Bixby; Kavitha Goyal
Journal:  Drugs Context       Date:  2020-02-25
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.